| Biotech | Agribusiness Partner | Type/Product Area | Amt. | Terms/Details (Month) | |||||
| Company** | (Symbol/Country) | ||||||||
| (Country) | |||||||||
| Acacia | American Cyanamid | Research collaboration; | ND | Acacia will provide chemical and bio- | |||||
| Biosciences | Co. (subsidiary of | use of functional genomics | logical profiles on a class of American | ||||||
| Inc.* | American Home | and bioinformatics to aid | Cyanamid's compounds for undisclosed | ||||||
| Products Corp.; | in selection and optimiza- | fee (1/98) | |||||||
| NYSE:AHP) | tion of lead compounds for | ||||||||
| crop protection products | |||||||||
| DuPont Agricultural | Research collaboration; | ND | Acacia will provide chemical and bio- | ||||||
| Enterprise (unit of E.I. | use of functional genomics | logical profiles on a class of duPont's | |||||||
| duPont de Nemours | and bioinformatics to aid | compounds for undisclosed fee (6/98) | |||||||
| and Co.; NYSE:DD) | in selection and optimiza- | ||||||||
| tion of lead compounds for | |||||||||
| crop protection products | |||||||||
| Novartis Crop Protec- | Research collaboration; | ND | Acacia will provide chemical and bio- | ||||||
| tion (unit of Novartis | use of functional genomics | logical profiles on a class of Novartis' | |||||||
| AG; Switzerland) | and bioinformatics to aid | compounds for undisclosed fee (8/98) | |||||||
| in selection and optimiza- | |||||||||
| tion of lead compounds for | |||||||||
| crop protection products | |||||||||
| Alanex Corp. | Zeneca Agrochemicals | Research collaboration; | ND | 3-year agreement; Alanex will provide | |||||
| (wholly owned | (division of Zeneca | use of Alanex' exploratory | compounds on non-exclusive basis but | ||||||
| subsidiary of | Ltd., NYSE:ZEN; U.K.) | chemical libraries for | Zeneca has right to exclusively license | ||||||
| Agouron Pharma- | screening in Zeneca's | any leads for use in agriculture, horti- | |||||||
| ceuticals Inc.) | high-throughput assays for | culture, forestry and public health; | |||||||
| agrochemicals | Alanex retains rights to human pharma- | ||||||||
| ceutical and animal health uses; Alanex | |||||||||
| gets up-front license fee, annual research | |||||||||
| support, milestones and royalties (6/98) | |||||||||
| BioSource | Dow AgroSciences | Research collaboration; | ND | Dow gets rights to all discovered genes | |||||
| Technologies | LLC (wholly owned | use of BioSource's fun- | that provide useful crop traits; Bio- | ||||||
| Inc.* | subsidiary of the Dow | ctional genomics technol- | Source retains rights to all pharma- | ||||||
| Chemical Co.; | ogy in Dow's high through- | ceutical and animal health applications; | |||||||
| NYSE:DOW) | put screens to create | 3-year agreement; other terms ND | |||||||
| specific crop traits | (9/98) | ||||||||
| CombiChem | Novartis Crop Protec- | Research collaboration; | ND | CombiChem will generate compounds | |||||
| Inc. | tion (unit of Novartis | use of CombiChem's com- | for in vivo testing in whole organisms; | ||||||
| AG; Switzerland) | putational drug discovery | CombiChem gets initial fee, research | |||||||
| program to generate com- | support and milestones; Novartis gets | ||||||||
| pounds for use as herbicides, | exclusive worldwide rights to develop | ||||||||
| fungicides and insectides | and market or sublicense products; | ||||||||
| CombiChem gets royalties (5/98) | |||||||||
| CuraGen Corp. | DuPont Agricultural | Research collaboration; | ND | ND (7/98) | |||||
| Enterprise (unit of E.I. | use of genomics technol- | ||||||||
| duPont de Nemours | ogies to characterize | ||||||||
| and Co.; NYSE:DD) | genetic components and | ||||||||
| metabolic pathways under- | |||||||||
| lying a DuPont crop pro- | |||||||||
| tection product | |||||||||
| CuraGen Corp. | Pioneer Hi-Bred | Expansion of 6/97 gene | ND | Pioneer will double its annual funding | |||||
| International Inc. | discovery collaboration; use | from $2.5M/year to $5M/year (4/98) | |||||||
| (NYSE:PHB) | of genomics technologies to | ||||||||
| discover genes responsible | |||||||||
| for agricultural seed product | |||||||||
| performance | |||||||||
| Ecogen Inc. | Monsanto Co. | Revision of 1/96 contract | ND | Ecogen will assist Monsanto in expand- | |||||
| (NYSE:MTC) | research agreement on | ing its capabilities in the Bt area; | |||||||
| enhanced Bt genes | amended agreement terminates 1/99 | ||||||||
| (1 year earlier than original) but Eco- | |||||||||
| gen still gets $10M total per original | |||||||||
| terms; Monsanto holds 12% of Ecogen | |||||||||
| stock (2/98) | |||||||||
| Enzo Biochem | Japan Tobacco Inc. | License agreement; | ND | Japan Tobacco gets license to use tech- | |||||
| Inc. | (Japan) | use of Enzo's genetic | nology in Japan; Enzo gets up-front fee, | ||||||
| antisense technology to | commercialization payments and royal- | ||||||||
| develop improved strains | ties (1/98) | ||||||||
| of rice | |||||||||
| EnzyMed Inc.* | Novartis Crop Protec- | Research collaboration; | ND | 3-year agreement; EnzyMed gets 1st | |||||
| tion (unit of Novartis | use of EnzyMed's combi- | option to perform lead optimization | |||||||
| AG; Switzerland) | natorial biocatalysis tech- | services on all active hits resulting | |||||||
| nology to create compound | from Novartis' screening of libraries | ||||||||
| libraries (potential crop | (6/98) | ||||||||
| protection agents) | |||||||||
| Exelixis Phar- | Bayer AG | Research collaboration; | $30M | Exelixis will identify and validate tar- | |||||
| maceuticals | (Germany) | use of Exelixis' model | gets and develop assays for high- | ||||||
| Inc.* | system genetics, genomics | throughput screening against Bayer's | |||||||
| and bioinformatics to | chemical compound libraries; Bayer will | ||||||||
| identify screening targets | evaluate, develop and commercialize | ||||||||
| for crop protection agents | products; Exelixis will also develop | ||||||||
| expressed sequence tag database for | |||||||||
| pest species of Bayer's choosing; | |||||||||
| Exelixis gets $30M total in license fees, | |||||||||
| research support and milestones, as well | |||||||||
| as royalties; 5-year collaboration (5/98) | |||||||||
| Flamel | Monsanto Co. | Research collaboration; | ND | This agreement expands scope of the | |||||
| Technologies | (NYSE:MTC) | use of Flamel's Agsome | parties' 8/96 collaboration; Flamel gets | ||||||
| SA (France) | agrochemical delivery | R & D funds, milestones and royalties; | |||||||
| system (nanoencapsulation) | Monsanto retains right to use Agsome | ||||||||
| to develop enhanced formu- | technology in other crop protection pro- | ||||||||
| lation of Roundup herbicide | ducts; Flamel retains rights in all areas | ||||||||
| outside of agrochemicals (1/98) | |||||||||
| Forage | Monsanto Co. | Research collaboration; | ND | Letter of intent signed; Monsanto will | |||||
| Genetics* | (NYSE:MTC) | incorporation of genes | contribute gene technology; Forage will | ||||||
| (wholly owned | with improved agronomic | provide alfalfa germplasm and transfor- | |||||||
| subsidiary of | traits into alfalfa germplasm; | mation technology; companies will | |||||||
| Research Seeds | initial focus is Roundup | broadly license all product improve- | |||||||
| Inc.) | Ready alfalfa | ments to alfalfa breeding and market- | |||||||
| ing organizations (6/98) | |||||||||
| Forage | Novartis Seed | Research collaboration; | ND | ND (8/98) | |||||
| Genetics* - | (unit of Novartis AG; | development, evaluation | |||||||
| (wholly owned | Switzerland) | and release of new NK | |||||||
| subsidiary of | brand alfalfa varieties with | ||||||||
| Research Seeds | Roundup Ready trait | ||||||||
| Inc.) | |||||||||
| Gene Logic Inc. | Hoechst Schering | Research collaboration; | $45M | 3-year exclusive agreement with possi- | |||||
| AgrEvo GmbH | use of functional genomics | ble extension for another 5 years; Gene | |||||||
| (joint venture between | to discover genes for crop | Logic will identify genes and develop | |||||||
| Hoechst AG and | protection and improvement | databases for various crops; AgrEvo | |||||||
| Schering AG; | gets access to Gene Logic's flow-thru | ||||||||
| Germany) | chip technology for further analysis of | ||||||||
| identified genes; Gene Logic gets data | |||||||||
| base fees and research funds of $45M | |||||||||
| over full term; it also gets milestones | |||||||||
| and royalties (7/98) | |||||||||
| GeneTrace | Monsanto Co. | Research collaboration; | $17.2M | Monsanto gets series of options to | |||||
| Systems Inc.* | (NYSE:MTC) | use of GeneTrace's tech- | (equity; | exclusively license all aspects of Gene- | |||||
| nology in plant and | % ND) | Trace's genomics technologies for | |||||||
| animal genomics; includes | plant and animal uses; as part of initial | ||||||||
| use of genotyping methods | agreement, Monsanto licensed geno- | ||||||||
| to improve seed germplasm | typing methods; GeneTrace gets $17.2M | ||||||||
| in crops (corn, soybeans) | total, including R & D funds, equipment | ||||||||
| purchases, supply agreements and | |||||||||
| equity investment (4/98) | |||||||||
| Microbix | Schering-Plough | Termination of collabor- | ND | Schering-Plough acquired collaboration | |||||
| Biosystems Inc. | Animal Health (unit | ation on adenovirus vector- | when it bought Mirobix' original part- | ||||||
| (TSE:MBX; Canada) | of Schering-Plough | based recombinant vaccine | ner Mallinckrodt Veterinary Inc. in 6/97; | ||||||
| Corp.; NYSE:SGP) | for rabies in companion | program does not fit into Schering- | |||||||
| animals | Plough's core business; Microbix re- | ||||||||
| acquired all product rights and will be | |||||||||
| paid for 2 outstanding milestones (7/98) | |||||||||
| Mycogen Corp. | Rhone-Poulenc Agro | Worldwide plant biotech | ND | In future, companies plan to incorporate | |||||
| (unit of Rhone- | alliance; pooling of assets | additional agronomic/quality traits (oil | |||||||
| Poulenc SA; NYSE: | to develop and market | or protein content); companies will | |||||||
| RP; France) | genetically modified plants | license products to seed companies; | |||||||
| and seeds containing multiple | Mycogen will also market directly in | ||||||||
| traits (especially for insect- | North and South America and Europe | ||||||||
| resistance and herbicide | (7/98) | ||||||||
| tolerance); initial focus on | |||||||||
| cotton and sugar cane | |||||||||
| Neurogen Corp. | Animal Health div- | License agreement; use of | ND | This is expansion of agreement between | |||||
| ision of Pfizer Inc. | Neurogen's small molecule | the companies covering human anxiety | |||||||
| (NYSE:PFE) | compounds that work via | disorders and dementia; Neurogen will | |||||||
| gamma amino butyric acid | identify drug candidates; Pfizer will de- | ||||||||
| neurotrasmitter system to | velop them and pays all costs; Neurogen | ||||||||
| develop drugs for treating | gets milestones and royalties (9/98) | ||||||||
| anxiety and cognitive | |||||||||
| dysfunction in companion | |||||||||
| animals | |||||||||
| Oxford | Dow AgroSciences | Research collaboration; | $1.2M | 18-month agreement; Oxford Asym- | |||||
| Asymmetry | LLC (wholly owned | discovery, synthesis and | metry gets $1.2M in fees, plus mile- | ||||||
| International | subsidiary of the Dow | screening of new chemical | stones and royalties for each compound | ||||||
| plc (LSE:OAI; U.K.) | Chemical Co.; | compounds for agricul- | developed (3/98) | ||||||
| NYSE:DOW) | tural applications | ||||||||
| Oxford | Pioneer Hi-Bred | Research collaboration; | $27.5M | 5-year collaboration; Oxford will con- | |||||
| GlycoSciences | International Inc. | use of Oxford GlycoSci- | struct protein expression databases for | ||||||
| plc (U.K.) | (NYSE:PHB) | ences' proteomics technol- | Pioneer; Oxford gets $12.5M up front | ||||||
| ogy with Pioneer's plant | plus $15M in R & D funds; it also gets | ||||||||
| gene database to discover | milestones and royalties (9/98) | ||||||||
| genes for improving agri- | |||||||||
| cultural seed products; | |||||||||
| initial focus on corn | |||||||||
| Performance | Dow AgroSciences | Research collaboration; | $1.2M | ND (9/98) | |||||
| Plants Inc.* | LLC (wholly owned | introduction of growth | |||||||
| (Canada) | subsidiary of the Dow | enhancement technology | |||||||
| Chemical Co.; | and augmented microbial | ||||||||
| NYSE:DOW) | and plant expression tech- | ||||||||
| nology (GET and AMPLE | |||||||||
| genes) to improve value and | |||||||||
| performance of canola and | |||||||||
| other crops | |||||||||
| Vaxcel Inc. | Heska Corp. | License agreement; | ND | Vaxcel gets up-front license fee, mile- | |||||
| (OTC Bulletin | (NASDAQ:HSKA) | use of Vaxcel's micro- | stones and royalties (8/98) | ||||||
| Board: VXCL) | encapsulation technologies | ||||||||
| in oral vaccines for com- | |||||||||
| panion animals | |||||||||
| Virus Research | Heska Corp. | Research collaboration | ND | Virus Research will supply Adjumer | |||||
| Institute Inc. | (NASDAQ:HSKA) | and license agreement; use | for formulation with Heska's antigens; | ||||||
| (merged with | of Virus Research's vaccine | Virus Research gets license fee, mile- | |||||||
| T Cell Sciences Inc. | delivery system Adjumer in | stones and royalties (2/98) | |||||||
| in 8/98 to form | vaccines for companion | ||||||||
| Avant Immuno- | animals | ||||||||
| therapeutics Inc.) | |||||||||
| NOTES: | |||||||||
| # This chart covers research and development-based collaborations and licensing agreements in agricultural biotechnology — including animal health, crops and agrochemicals — announced between 1/1/98 and 10/19/98. It encompasses both new agreements and those that have been modified or terminated. | |||||||||
| ND = Not disclosed, reported and/or available; LSE = London Stock Exchange; TSE = Toronto Stock Exchange | |||||||||
| * Private companies are indicated with an asterisk. | |||||||||
| ** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 12-13. | |||||||||
